Sklip Inc

Sklip Inc. empowers healthcare providers and their patients to find skin cancers, earlier, with a software-based digital health platform app that incorporates our subscription-based, proprietary Ai-driven software with FDA Breakthrough Designation Status. Sklip Ai*(artificial intelligence) accelerates non-invasive skin cancer triage time from days to seconds, increases procedure-related revenue for dermatology offices, reduces dermatology visit wait times from months to days, reduces primary care referrals requirements, and connects worried consumers to Sklip verified dermatology offices where they can get a visit in under 14 days. The company was Founded by Dr. Alexander Witkowski MD, PhD and his team developed the patent pend. Sklip smartphone dermatoscope and Sklip Ai*. Dr. Witkowski is internationally recognized for his expertise in early skin cancer detection and was voted Chair of the American Academy of Dermatology Cutaneous Imaging Expert Resource Group in 2023, the highest leadership position for skin cancer triage and diagnostics in the United States. Dr. Witkowski holds the Guinness World Record for smallest skin cancer detected (0.65 mm / 0.0256 in. diameter melanoma skin cancer), PubMed peer-reviewed. The following are in the Sklip product portfolio: Sklip artificial intelligence (Ai) is proprietary, has the highest in-class accuracy, validated with FDA Breakthrough Designation Status. Sklip smartphone dermatoscope is patent pending, can be used on 99% of smartphones in the global market, FDA Class 1 registered. Sklip app digital health platform is available for public download, integrated Ai-driven software, subscription-based SaaS as low as $2.99 per mole.